On June 22, Zai Lab fell 5.08% in regular trading, trading at HK$13.7/share, with turnover of HK$54.50 million.

On the news front, partner Novocure announced on June 18 that its Phase III TRIDENT trial evaluating Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM) failed to meet its primary overall survival (OS) endpoint. The two treatment arms showed median OS of 17.7 months and 17.5 months respectively, with HR of 0.953 and a p-value of 0.519, indicating no statistically significant benefit from earlier initiation of TTFields. Novocure's stock plunged approximately 20% on the news.

Zai Lab holds the Greater China rights to TTFields, marketed domestically under the OPTUNE brand. The product contributed approximately US$48 million in sales in 2025. While the TRIDENT trial specifically tested earlier use of TTFields rather than challenging the existing approved indication, the clinical failure raises concerns about the product's pipeline expansion value and future growth potential in Zai Lab's portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)